Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML) Risk

Predicts the risk of PML in patients treated with Natalizumab

NeoHealth® ID 34932 · updated 2/22/2023

neobook · a NeoHealth® product

South African clinical reference: NDOH Standard Treatment Guidelines, Essential Medicines List, and bedside calculators.

Browse

About

Content sourced from the South African National Department of Health (NDOH) — public-domain works of government. Not medical advice.

Browse clinical reference

Guidelines & EML

Reference

Guidelines & EML

Reference